| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Investigations |
1 Department of Neurosurgery, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
2 PET/Biomedical Cyclotron Unit, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
3 Department of Neuroradiology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
4 Department of Anesthesiology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
5 Department of Neuropathology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
We compared the contributions of the labeled tracers 11C-methionine (Met) and 18F-FDG for PET-guided stereotactic biopsy of brain gliomas. Methods: In 32 patients with glioma, stereotactic Met PET and 18F-FDG PET were integrated in the planning of stereotactic brain biopsy. PET images were analyzed to determine which tracer offered the best information for target definition. The stereotactic coregistration of PET images allowed accurate comparison of the level, distribution, and extent of uptake for both tracers according to tumor location and grade. Results: A histologic diagnosis was obtained for all patients. All gliomas had an area of abnormal Met uptake, and 27 showed abnormal 18F-FDG uptake. 18F-FDG was used for target selection when its uptake was higher in tumor than in gray matter (14 gliomas). Seven were in the basal ganglia or brain stem. Met was used for target selection when there was no 18F-FDG uptake or when 18F-FDG uptake was equivalent to that in the gray matter (18 gliomas). Thirteen were in the cortex. Sixty-one of the 70 stereotactic trajectories obtained from the 32 patients were based on PET-defined targets and had an area of abnormal Met uptake. These 61 Met-positive trajectories always yielded a diagnosis of tumor. All nondiagnostic trajectories (n = 9) were obtained in areas with no increased uptake of Met. In all patients with increased uptake of both tracers, the focus of highest Met uptake corresponded to the focus of highest 18F-FDG uptake. However, the extent of uptake of both tracers was variable. Conclusion: Distributions of highest Met and 18F-FDG uptake are similar in brain gliomas. Because Met provides a more sensitive signal, it is the molecule of choice for single-tracer PET-guided neurosurgical procedures in gliomas.
Key Words: stereotactic biopsy • PET • 18F-FDG • 11C-methionine • glioma
Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  C. Plathow and W. A. Weber Tumor Cell Metabolism Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Coope, J. Cizek, C. Eggers, S. Vollmar, W.-D. Heiss, and K. Herholz Evaluation of Primary Brain Tumors Using 11C-Methionine PET with Reference to a Normal Methionine Uptake Map J. Nucl. Med., December 1, 2007; 48(12): 1971 - 1980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Chen Clinical Applications of PET in Brain Tumors J. Nucl. Med., September 1, 2007; 48(9): 1468 - 1481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ceyssens, K. Van Laere, T. de Groot, J. Goffin, G. Bormans, and L. Mortelmans [11C]Methionine PET, Histopathology, and Survival in Primary Brain Tumors and Recurrence AJNR Am. J. Neuroradiol., August 1, 2006; 27(7): 1432 - 1437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pauleit, F. Floeth, K. Hamacher, M. J. Riemenschneider, G. Reifenberger, H.-W. Muller, K. Zilles, H. H. Coenen, and K.-J. Langen O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas Brain, March 1, 2005; 128(3): 678 - 687. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
